GSA Capital Partners LLP Grows Stock Holdings in aTyr Pharma, Inc. $ATYR

GSA Capital Partners LLP increased its stake in shares of aTyr Pharma, Inc. (NASDAQ:ATYR) by 272.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,630,638 shares of the company’s stock after buying an additional 1,923,907 shares during the period. GSA Capital Partners LLP’s holdings in aTyr Pharma were worth $2,060,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in ATYR. Profund Advisors LLC purchased a new stake in aTyr Pharma during the third quarter worth about $27,000. California State Teachers Retirement System purchased a new stake in aTyr Pharma during the second quarter worth about $28,000. Kingswood Wealth Advisors LLC purchased a new stake in shares of aTyr Pharma in the fourth quarter valued at about $41,000. Legal & General Group Plc purchased a new stake in shares of aTyr Pharma in the second quarter valued at about $49,000. Finally, Prudential Financial Inc. purchased a new stake in shares of aTyr Pharma in the second quarter valued at about $63,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

aTyr Pharma Price Performance

Shares of NASDAQ ATYR opened at $0.48 on Wednesday. aTyr Pharma, Inc. has a 12-month low of $0.40 and a 12-month high of $7.29. The company has a market capitalization of $47.36 million, a PE ratio of -0.66 and a beta of 0.66. The firm’s 50-day moving average is $0.80 and its two-hundred day moving average is $0.80.

aTyr Pharma (NASDAQ:ATYR) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. On average, analysts forecast that aTyr Pharma, Inc. will post -0.66 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on ATYR. Wall Street Zen raised shares of aTyr Pharma from a “sell” rating to a “hold” rating in a report on Sunday. Jefferies Financial Group reaffirmed a “buy” rating on shares of aTyr Pharma in a report on Friday, March 6th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $25.67.

aTyr Pharma Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.